Billing Beat

Blues highlight medical, benefit policy changes for Genetic Tests

May 24, 2012

The following information highlights the medical, benefit policy changes for some Genetic Testing.

• NEW PAYABLE PROCEDURES 81405, 81408, 88299 The safety and effectiveness of genetic testing for Marfan syndrome (MFS) have been established. It may be considered a useful diagnostic option when indicated. This policy is effective March 1, 2012.
• POLICY CLARIFICATIONS 81292-81301, S3833, S3834 The inclusionary guidelines for the Genetic Testing for Inherited Susceptibility to Colorectal Cancer, Including Microsatellite Instability and Immunohistochemistry Testing policy have been updated, effective May 1, 2012.
Payable code: S3855
Experimental codes: 83520, 83912, S3852		 Medical Policy has been determined for genetic testing and biochemical markers for Alzheimer’s Disease. This policy is effective May 1, 2012.
• EXPERIMENTAL PROCEDURES 88299 NOTCH3 testing for the diagnosis of CADASIL is considered experimental. The clinical utility of genetic testing for CADASIL has not been assessed in published studies to date. This policy is effective May 1, 2012.

Sign up for Billing Beat